Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the dose regimen of Ispinesib in combination with carboplatin in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion and carboplatin is dosed by 30 minute intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with Ispinesib. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00136578
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date October 20, 2004
Completion date October 25, 2006

See also
  Status Clinical Trial Phase
Completed NCT03315091 - Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours Phase 1
Completed NCT01921140 - To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours Phase 1
Completed NCT00732420 - Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors Phase 1
Recruiting NCT03572192 - Tissue Collection Framework To Improve Outcomes In Solid Tumours
Completed NCT02360345 - Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly Phase 1
Completed NCT02264418 - Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours Phase 1
Completed NCT02093351 - To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer Phase 1
Completed NCT01956669 - Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Phase 2
Recruiting NCT02215850 - Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours Phase 1
Recruiting NCT02263950 - A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT01931761 - Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers Phase 1
Completed NCT01900028 - To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours Phase 1
Completed NCT01184274 - A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia Phase 1
Withdrawn NCT03266159 - A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors Phase 2
Active, not recruiting NCT01894256 - Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function Phase 1
Completed NCT01974349 - To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Phase 1
Completed NCT02923947 - Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment Phase 1
Completed NCT02063204 - To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects Phase 1
Completed NCT02056392 - To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers Phase 1
Completed NCT00742131 - A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors Phase 1